|
1
|
Gaur P, Hunt CR and Pandita TK: Emerging
therapeutic targets in esophageal adenocarcinoma. Oncotarget.
7:48644–48655. 2016.PubMed/NCBI
|
|
2
|
Edgren G, Adami HO, Weiderpass E and Nyrén
O: A global assessment of the oesophageal adenocarcinoma epidemic.
Gut. 62:1406–1414. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rubenstein JH and Shaheen NJ:
Epidemiology, diagnosis, and management of esophageal
adenocarcinoma. Gastroenterology. 149:302–17.e1. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pennathur A, Farkas A, Krasinskas AM,
Ferson PF, Gooding WE, Gibson MK, Schuchert MJ, Landreneau RJ and
Luketich JD: Esophagectomy for T1 esophageal cancer: Outcomes in
100 patients and implications for endoscopic therapy. Ann Thorac
Surg. 87:1048–1054, discussion 1054–1055. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matsumoto R, Matsumoto H, Seki M, Hata M,
Asano Y, Kanegasaki S, Stevens RL and Hirashima M: Human ecalectin,
a variant of human galectin-9, is a novel eosinophil
chemoattractant produced by T lymphocytes. J Biol Chem.
273:16976–16984. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matsushita N, Nishi N, Seki M, Matsumoto
R, Kuwabara I, Liu FT, Hata Y, Nakamura T and Hirashima M:
Requirement of divalent galactoside-binding activity of
ecalectin/galectin-9 for eosinophil chemoattraction. J Biol Chem.
275:8355–8360. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matsumoto R, Hirashima M, Kita H and
Gleich GJ: Biological activities of ecalectin: A novel
eosinophil-activating factor. J Immunol. 168:1961–1967. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saita N, Goto E, Yamamoto T, Cho I,
Tsumori K, Kohrogi H, Maruo K, Ono T, Takeya M, Kashio Y, et al:
Association of galectin-9 with eosinophil apoptosis. Int Arch
Allergy Immunol. 128:42–50. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Asakura H, Kashio Y, Nakamura K, Seki M,
Dai S, Shirato Y, Abedin MJ, Yoshida N, Nishi N, Imaizumi T, et al:
Selective eosinophil adhesion to fibroblast via IFN-gamma-induced
galectin-9. J Immunol. 169:5912–5918. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dai SY, Nakagawa R, Itoh A, Murakami H,
Kashio Y, Abe H, Katoh S, Kontani K, Kihara M, Zhang SL, et al:
Galectin-9 induces maturation of human monocyte-derived dendritic
cells. J Immunol. 175:2974–2981. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nobumoto A, Oomizu S, Arikawa T, Katoh S,
Nagahara K, Miyake M, Nishi N, Takeshita K, Niki T, Yamauchi A, et
al: Galectin-9 expands unique macrophages exhibiting plasmacytoid
dendritic cell-like phenotypes that activate NK cells in
tumor-bearing mice. Clin Immunol. 130:322–330. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wiersma VR, De Bruyn M, Helfrich W and
Bremer E: Therapeutic potential of Galectin-9 in human disease. Med
Res Rev. 33 Suppl 1:E102–E126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fujihara S, Mori H, Kobara H, Rafiq K,
Niki T, Hirashima M and Masaki T: Galectin-9 in cancer therapy.
Recent Pat Endocr Metab Immune Drug Discov. 7:130–137. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kashio Y, Nakamura K, Abedin MJ, Seki M,
Nishi N, Yoshida N, Nakamura T and Hirashima M: Galectin-9 induces
apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol.
170:3631–3636. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu LH, Nakagawa R, Kashio Y, Ito A, Shoji
H, Nishi N, Hirashima M, Yamauchi A and Nakamura T:
Characterization of galectin-9-induced death of Jurkat T cells. J
Biochem. 141:157–172. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kobayashi T, Kuroda J, Ashihara E, Oomizu
S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N,
et al: Galectin-9 exhibits anti-myeloma activity through JNK and
p38 MAP kinase pathways. Leukemia. 24:843–850. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kuroda J, Yamamoto M, Nagoshi H, Kobayashi
T, Sasaki N, Shimura Y, Horiike S, Kimura S, Yamauchi A, Hirashima
M, et al: Targeting activating transcription factor 3 by Galectin-9
induces apoptosis and overcomes various types of treatment
resistance in chronic myelogenous leukemia. Mol Cancer Res.
8:994–1001. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kageshita T, Kashio Y, Yamauchi A, Seki M,
Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T and Hirashima M:
Possible role of galectin-9 in cell aggregation and apoptosis of
human melanoma cell lines and its clinical significance. Int J
Cancer. 99:809–816. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wiersma VR, De Bruyn M, van Ginkel RJ,
Sigar E, Hirashima M, Niki T, Nishi N, Samplonius DF, Helfrich W
and Bremer E: The glycan-binding protein galectin-9 has direct
apoptotic activity toward melanoma cells. J Invest Dermatol.
132:2302–2305. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fujita K, Iwama H, Sakamoto T, Okura R,
Kobayashi K, Takano J, Katsura A, Tatsuta M, Maeda E, Mimura S, et
al: Galectin-9 suppresses the growth of hepatocellular carcinoma
via apoptosis in vitroin vivo. Int J Oncol. 46:2419–2430.
2015.PubMed/NCBI
|
|
22
|
Kobayashi K, Morishita A, Iwama H, Fujita
K, Okura R, Fujihara S, Yamashita T, Fujimori T, Kato K, Kamada H,
et al: Galectin-9 suppresses cholangiocarcinoma cell proliferation
by inducing apoptosis but not cell cycle arrest. Oncol Rep.
34:1761–1770. 2015.PubMed/NCBI
|
|
23
|
Tadokoro T, Morishita A, Fujihara S, Iwama
H, Niki T, Fujita K, Akashi E, Mimura S, Oura K, Sakamoto T, et al:
Galectin-9: An anticancer molecule for gallbladder carcinoma. Int J
Oncol. 48:1165–1174. 2016.PubMed/NCBI
|
|
24
|
Nishi N, Itoh A, Fujiyama A, Yoshida N,
Araya S, Hirashima M, Shoji H and Nakamura T: Development of highly
stable galectins: Truncation of the linker peptide confers
protease-resistance on tandem-repeat type galectins. FEBS Lett.
579:2058–2064. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schutte B, Henfling M, Kölgen W, Bouman M,
Meex S, Leers MP, Nap M, Björklund V, Björklund P, Björklund B, et
al: Keratin 8/18 breakdown and reorganization during apoptosis. Exp
Cell Res. 297:11–26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Towbin H, Staehelin T and Gordon J:
Electrophoretic transfer of proteins from polyacrylamide gels to
nitrocellulose sheets: Procedure and some applications. Proc Natl
Acad Sci USA. 76:4350–4354. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Irie A, Yamauchi A, Kontani K, Kihara M,
Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H, et al:
Galectin-9 as a prognostic factor with antimetastatic potential in
breast cancer. Clin Cancer Res. 11:2962–2968. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kramer G, Erdal H, Mertens HJ, Nap M,
Mauermann J, Steiner G, Marberger M, Bivén K, Shoshan MC and Linder
S: Differentiation between cell death modes using measurements of
different soluble forms of extracellular cytokeratin 18. Cancer
Res. 64:1751–1756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wiersma VR, De Bruyn M, Wei Y, van Ginkel
RJ, Hirashima M, Niki T, Nishi N, Zhou J, Pouwels SD, Samplonius
DF, et al: The epithelial polarity regulator LGALS9/galectin-9
induces fatal frustrated autophagy in KRAS mutant colon carcinoma
that depends on elevated basal autophagic flux. Autophagy.
11:1373–1388. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takano J, Morishita A, Fujihara S, Iwama
H, Kokado F, Fujikawa K, Fujita K, Chiyo T, Tadokoro T, Sakamoto T,
et al: Galectin-9 suppresses the proliferation of gastric cancer
cells in vitro. Oncol Rep. 35:851–860. 2016.PubMed/NCBI
|
|
32
|
Fulda S: Targeting apoptosis for
anticancer therapy. Semin Cancer Biol. 31:84–88. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Waugh DJ and Wilson C: The interleukin-8
pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ogura M, Takeuchi H, Kawakubo H, Nishi T,
Fukuda K, Nakamura R, Takahashi T, Wada N, Saikawa Y, Omori T, et
al: Clinical significance of CXCL-8/CXCR-2 network in esophageal
squamous cell carcinoma. Surgery. 154:512–520. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ladeiro Y, Couchy G, Balabaud C,
Bioulac-Sage P, Pelletier L, Rebouissou S and Zucman-Rossi J:
MicroRNA profiling in hepatocellular tumors is associated with
clinical features and oncogene/tumor suppressor gene mutations.
Hepatology. 47:1955–1963. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tanaka K, Miyata H, Yamasaki M, Sugimura
K, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M and
Doki Y: Circulating miR-200c levels significantly predict response
to chemotherapy and prognosis of patients undergoing neoadjuvant
chemotherapy for esophageal cancer. Ann Surg Oncol. 20 Suppl
3:S607–S615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hamano R, Miyata H, Yamasaki M, Kurokawa
Y, Hara J, Moon JH, Nakajima K, Takiguchi S, Fujiwara Y, Mori M, et
al: Overexpression of miR-200c induces chemoresistance in
esophageal cancers mediated through activation of the Akt signaling
pathway. Clin Cancer Res. 17:3029–3038. 2011. View Article : Google Scholar : PubMed/NCBI
|
